By Denny Jacob
Gilead Sciences has discontinued its Phase 3 study of magrolimab in higher-risk myelodysplastic syndromes.
The biopharmaceutical company said on Friday the study was discontinued due to futility based on a planned analysis. Gilead said it recommends discontinuing treatment with magrolimab in patients with myelodysplastic syndromes,…